Wenwei Ouyang

Mr. Wenwei Ouyang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LWLin Wei
Lin Wei
YLYueming Luo
Yueming Luo
XZXiaopei Zhang
Xiaopei Zhang
YLYangchen Liu
Yangchen Liu
MGMartin Gasser
Martin Gasser
MLMeizhen Lin
Meizhen Lin

20 November 2025 in Phytomedicine
Verified
Journal Article
Closed access
XGXiaohui Guo
Xiaohui Guo
TCTing Cheng
Ting Cheng
MXMeiling Xuan
Meiling Xuan
GLGeng Li
Geng Li
LZLi Zhou
Li Zhou
ZWZehuai Wen
Zehuai Wen

4 October 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
QHQian Huang
Qian Huang
XGXiaohui Guo
Xiaohui Guo
MXMeiling Xuan
Meiling Xuan
WOWenwei Ouyang
Wenwei Ouyang
ZWZehuai Wen
Zehuai Wen
Introduction. Atopic dermatitis (AD) and diarrhea-predominant irritable bowel syndrome (IBS-D) are two recurrent diseases with limited effective treatments. In Chinese Medicine (CM) theory, they may share dampness pattern as the same dominant pathogenesis at a certain stage and, thus, can be treated with the same method. While Chinese herbal formula Huoxiang Zhengqi (HXZQ) has been reported as an effective dampness-resolving therapy for both AD and IBS-D, further high-quality clinical studies are still needed. In addition, HXZQ lacks accurate clinical positioning based on CM patterns. Therefore, we utilize a master protocol design to evaluate HXZQ for dampness pattern simultaneously in AD and IBS-D, with the aim of identifying the pattern-defined population of HXZQ. Methods and Analysis. This master protocol design includes two randomized controlled trials (RCTs) and a real-world observational study. Based on two registry cohorts of AD and IBS-D, patients with dampness pattern will be enrolled in the RCTs to receive either HXZQ oral liquid or a placebo for 4 weeks and then will be followed up for another 4 weeks, while patients with nondampness pattern will constitute the observational study and experience a 12-week follow-up. A total of 678 AD patients and 322 IBS-D patients will be recruited from 14 hospitals in China over a 3-year period. The eczema area and severity index (EASI) and the proportion of responders for adequate relief (AR) are the primary outcomes in AD and IBS-D, respectively. Analysis will be undertaken separately in each substudy, and then an overall analysis combining multiple subgroups will be performed to comprehensively investigate the effect of HXZQ. Discussion. This study will provide high-quality efficacy evidence of HXZQ for AD and IBS-D patients and give an example of postmarketing evaluation for CM products under the pattern dominating different disease research model. The study is registered with ChiCTR1900026700 and ChiCTR1900026837.

11 July 2018 in Trials
Verified
Journal Article
Open access
QLQian Li
Qian Li
BZBeiping Zhang
Beiping Zhang
SHShaogang Huang
Shaogang Huang
WOWenwei Ouyang
Wenwei Ouyang
JXJian-Hui Xie
Jian-Hui Xie
XYXiao-Bo Yang
Xiao-Bo Yang
Background: Irritable bowel syndrome (IBS) is a chronic, recurring condition, prevalent in the general population. Current medication treatments usually leave patients undertreated. Nowadays, Chinese medicine (CM) is being considered as a promising treatment approach for IBS. However, due to methodological limitations, there is no strong evidence to support CM. Although IBS relapses are common, the relapse assessment has always been neglected in CM study designs. Meanwhile, in clinical practice and studies, it has been found that certain CM formulas can only benefit certain kinds of patients. Discovering what population and illness characteristics likely respond to outcomes may help improve the effectiveness of CM. The aims of this study are to evaluate the efficacy and safety of Tiao-Chang Ke-Min (TCKM) granules for IBS, especially in reducing IBS symptoms' relapse, by a highquality randomized controlled trial and then to optimize the indication of the TCKM granules. Methods/design: This is a parallel-group, randomized, double-blind, placebo-controlled trial embedded with outcome predictive factors. Eligible patients with diarrhea-predominant IBS will be randomized into either a TCKM granule group or a placebo group. Patients from both groups will receive health education. The treatment duration is 4 weeks and the follow-up is 12 weeks. The primary outcome is global improvement measured with adequate relief (AR). The second outcome measures include time until relief, time until first relapse, total relapse times, long-term effectiveness, individual symptoms, IBS-Symptom Severity Score (IBS-SSS), IBS-Quality of Life Questionnaire (IBS-QOL), and Hospital Anxiety and Depression Scale (HADS). Predictive factors associated with patient and illness characteristics have been widely collected. These factors will be embedded in this trial for further identification. Discussion: This trial may provide high-quality evidence on the efficacy and safety of TCKM granules for IBS and a more accurate indication. Importantly, this trial will provide a new research method for improving the therapeutic effects of CM for clinicians and researchers. To address IBS relapse assessment, a series of special definitions of relapse incidents has been made for this trial.

4 October 2024 in Phytomedicine
Verified
Journal Article
Closed access
LZLi Zhou
Li Zhou
JTJun Tan
Jun Tan
GLGeng Li
Geng Li
XCXiankun Chen
Xiankun Chen
MXMeiling Xuan
Meiling Xuan
ZWZehuai Wen
Zehuai Wen

1 January 2026 in Journal of Nursing Management
Verified
Journal Article
Open access
HCHui-Fen Chen
Hui-Fen Chen
XLXing-Le Liang
Xing-Le Liang
YHYan Han
Yan Han
YSYu-Han Shen
Yu-Han Shen
XZXian-Long Zhang
Xian-Long Zhang
YWYi-fan Wu
Yi-fan Wu
Background: Self‐management (SMP) is a novel treatment comprised of multidimensional interventions. Researchers have reported its reliable effects on short‐term improvements in surrogate indicators like 24‐h urinary protein excretion and systolic blood pressure. However, whether it has any effect on long‐term changes in other surrogate indicators and chronic kidney disease (CKD) endpoints remains unclear. Methods: Patients with CKD stages 3‐4 were grouped into either a SMP group or a nonself‐management (non‐SMP) group whether they had complied any of five characterized elements: regular visits, medication adjustment, nutritional intervention, lifestyle modification, education, and behavior guide. We used 1:1 nearest‐neighbor propensity score matching (PSM) to balance between‐group differences. Cox regression was used to explore the long‐term association between SMP and composite outcomes (all‐cause mortality, end‐stage kidney disease (ESKD), ≥ 50% decline in estimated glomerular filtration rate (eGFR), or doubling of serum creatinine (SCr) from baseline). Linear mixed‐effects (LME) model and marginal means comparisons were used to surrogate indicators analysis. Results: The study included 1160 patients with a median follow‐up of 27.20 months. Among them, 580 individuals were in the SMP group and 580 were in the non‐SMP group. In the non‐SMP group, the median follow‐up was 24.48 (12.21, 43.39) months with 174 (30.00%) events, whereas the SMP group had a median follow‐up of 29.34 (14.75, 42.00) months with 134 (23.10%) composite outcomes. Participation in a SMP program was associated with a 30.9% reduction in CKD progression risk (hazard ratio (HR) of composite outcome: 0.691, 95% CI: 0.549–0.869, and p = 0.002). LME and marginal means comparison indicated that patients with SMP had higher mean difference of eGFR and serum albumin (Alb) than the non‐SMP individuals (mean difference of eGFR: 1.791 (0.721, 2.861) mL/min/1.73 m 2 , p = 0.001; marginal mean difference of eGFR: 2.560 (1.660, 3.470) mL/min/1.73 m 2 , p < 0.0001; mean difference of Alb: 0.654 (0.202, 1.105) g/L, p = 0.005; and marginal mean difference of Alb: 0.460 (0.166, 0.753) g/L, p = 0.002). Conclusion: SMP programs are associated with a 30.9% reduction in CKD progression risk and improvements in kidney function and nutrition‐related surrogate markers, benefiting CKD patients in stages 3‐4.